Evidence map›Paper›PMID 38034530›Full record

ArticleFrontiers in medicine2023

18 months follow-up of deep molecular response 4.5 (MR

Bingbing Wen, Yuming Zhang, Haiqing Lin, Jin Lou, Chuangqing Tu, Yirong Jiang, Xiaolian Liu, Yan Chen, Huiqing He, Zelin Liu and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 59% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 12 institutions in 1 country.

Bingbing Wen *Department of Hematology, The Second People's Hospital of Shenzhen, The First Affiliated Hospital of Shenzhen University, Shenzhen, China.
Yuming Zhang *Department of Hematology, Affiliated General Hospital of Guangdong Medical University, Zhanjiang, China.
Haiqing Lin *Department of Hematology, Shenzhen People's Hospital, Shenzhen, China.
Jin LouDepartment of Hematology, The Second People's Hospital of Shenzhen, The First Affiliated Hospital of Shenzhen University, Shenzhen, China.
Chuangqing TuDepartment of Hematology, Shenzhen Baoan People's Hospital, Shenzhen, China.
Yirong JiangDepartment of Hematology, Dongguan People's Hospital, Dongguan, China.
Xiaolian LiuDepartment of Hematology, Gaozhou People Hospital, Gaozhou, China.
Yan ChenDepartment of Hematology, The Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen, China.
Huiqing HeDepartment of Hematology, Zhongshan City People's Hospital, Zhongshan, China.
Zelin LiuDepartment of Hematology, Huazhong University of Science and Technology Union Shenzhen Hospital (Nanshan Hospital), Shenzhen, China.
Xiaoling XieDepartment of Hematology, Huizhou Municipal Central Hospital, Huizhou, China.
Wangxiang HuangDepartment of Hematology, Shenzhen Longgang Central Hospital, Shenzhen, China.
Liping PangDepartment of Hematology, Peking University Shenzhen Hospital, Shenzhen, China.
Xin DuDepartment of Hematology, The Second People's Hospital of Shenzhen, The First Affiliated Hospital of Shenzhen University, Shenzhen, China.
Shenzhen Second People's Hospital · CNDongguan People’s Hospital · CNGaozhou People's Hospital · CNGuangdong Medical College · CNHuazhong University of Science and Technology · CNHuizhou Central People's Hospital · CNLonggang Central Hospital · CNPeking University Shenzhen Hospital · CNShenzhen Bao'an District People's Hospital · CNShenZhen People’s Hospital · CNSun Yat-sen University · CNZhongshan People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Early stable deep molecular response (DMR) to nilotinib is associated with goal of treatment-free remission (TFR) in patients with chronic-phase chronic myeloid leukemia (CML-CP). It is important to early distinguish between patients who can achieve a DMR and those who are fit for TFR. Methods: We performed a multicenter study to explore the early cumulative MR Results and discussion: The cumulative MR

Indexed as

18 monthschronic-phase chronic myeloid leukemiadeep molecular responsenewly diagnosednilotinib

Identifiers

PMID38034530
PMCPMC10687434
OpenAlexW4388723061

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.